Pharmacological treatment of osteoporosis in old age

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–795.

2. Khosla S. Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci 2013; 68(10): 1226–1235.

3. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513–521.

4. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2013; 8(1): 136.

5. Gullberg B, Johnell O, Kanis J. World-wide projections for hip fracture. Osteoporos Int 1997; 7: 407–413.

6. Mitchell WK, Williams J, Atherton P, et al. Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol 2012; 3: 260.

7. Kirk B, Miller S, Zanker J, Duque G. A clinical guide to the pathophysiology, diagnosis and treatment of osteosarcopenia. Maturitas 2020; 140: 27–33.

8. Amin S, Achenbach SJ, Atkinson EJ, et al. Trends in fracture incidence: a population-based study over 20 years. J Bone Miner Res 2014; 29: 581–589.

9. Ström O, Borgström F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU. Arch Osteoporos 2011; 6: 59–155.

10. Chevalley T, Guilley E, Herrmann FR, et al. Incidence of hip fracture over a 10-year period (1991– 2000): reversal of a secular trend. Bone 2007; 40: 1284–1289.

11. Gielen E, Verschueren S, O’Neill TW, et al. Musculoskeletal frailty: a geriatric syndrome at the core of fracture occurrence in older age. Calcif Tissue Int 2012; 91(3): 161–177.

12. International Osteoporosis Foundation [webpage on the Internet]. Facts and statistics. Available from: https: //www.iofbonehealth. org/facts-statistics. [accessed December 1, 2016].

13. Kaufman JM. Management of osteoporosis in older men. Aging Clin Exp Res. 2021; 33(6): 1439– 1452.

14. Haentjens P, Magaziner J, Colon- -Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152(6): 380–390.

15. Gielen E, Vanderschueren D, Callewaert F, Boonen S. Osteoporosis in men. Best Prac Res Clin Endocrinol Metab 2011; 25(2): 321–335.

16. Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163(18): 2165–2172.

17. Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. Arch Osteoporos 2013; 8: 136.

18. Vandenbroucke A, Luyten FP, Flamaing J, Gielen E. Pharmacological treatment of osteoporosis in the oldest old. Clin Interv Aging 2017; 12(6): 1065–1077.

19. Broy SB. The Vertebral Fracture Cascade: Etiology and Clinical Implications. J Clin Densitom 2016; 19(1): 29–34.

20. Kanis JA, Johansson H, Odén A, et al. Characteristics of recurrent fractures. Osteoporos Int 2018; 29(8): 1747–57.

21. Kanis JA, Harvey NC, McCloskey E, et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Osteoporos Int 2020; 31(1): 1–12.

22. Kanis JA, Cooper C, Rizzoli R, Reginster J-Y. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2019; 30(1): 3–44.

23. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48(4): 601.

24. Kojima G. Frailty as a Predictor of Future Falls Among Community-Dwelling Older People: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc 2015; 16(12): 1027–33.

25. Dent E, Morley JE, Cruz-Jentoft AJ, et al. Physical Frailty: ICFSR International Clinical Practice Guidelines for Identification and Management. J Nutr Health Aging 2019; 23(9): 771–87.

26. Genaro PS, Martini LA. Effect of protein intake on bone and muscle mass in the elderly. Nutr Rev 2010; 68: 616–623.

27. Raynaud-Simon A, Revel-Delhom C, Hebuterne X. Clinical practice guidelines from the French Health High Authority: nutritional support strategy in protein-energy malnutrition in the elderly. Clin Nutr 2011; 30: 312–319.

28. Livingstone C. Insulin-like growth factor-I (IGF-I) and clinical nutrition. Clin Sci (Lond) 2013; 125: 265–280.

29. Mithal A, Bonjour JP, Boonen S, et al. Impact of nutrition on muscle mass, strength, and performance in older adults. Osteoporos Int 2013; 24: 1555–1566.

30. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001; 22(4): 477–501.

31. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367: 40–49.

32. Boersma D, Demontiero O, Mohtasham AZ, et al. Vitamin D status in relation to postural stability in the elderly. J Nutr Health Aging 2012; 16: 270–275.

33. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88(12): 5766–5772.

34. Cauley JA, Lacroix AZ, Wu L, et al. Serum 25-hydroxy vitamin D concentrations and risk for hip fractures. Ann Intern Med 2008; 149(4): 242–250.

35. Aspell N, Laird E, Healy M, et al. Vitamin D deficiency is associated with impaired muscle strength and physical performance in community- dwelling older adults: findings from the English Longitudinal Study of Ageing. Clin Interv Aging 2019; 14: 1751–1761.

36. Aspell N, Laird E, Healy M, et al. The prevalence and determinants of vitamin D status in communitydwelling older adults: results from the English Longitudinal Study of Ageing (ELSA). Nutrients 2019; 11(6): 1253.

37. Zhao JG, Zeng XT, Wang J, Liu L. Association between calcium or vitamin D supplementation and fracture incidence in community dwelling older adults: a systematic review and meta-analysis. JAMA 2017; 318(24): 2466–2482.

38. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009.

39. Gaksch M, Jorde R, Grimnes G, et al. Vitamin D and mortality: individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium. PLoS One 2017; 12(2): e0170791.

40. Crowe FL, Thayakaran R, Gittoes N, et al. Non-linear associations of 25-hydroxyvitamin D concentrations with risk of cardiovascular disease and all-cause mortality: results from the health improvement network (THIN) database. J Steroid Biochem Mol Biol 2019; 195: 105480.

41. Dawson-Hughes B, Mithal A, Bonjour JP, et al. IOF position statement: vitamin D recommendations for older adults. Osteoporos Int 2010; 21(7): 1151–1154.

42. Bouillon R, Van Schoor NM, Gielen E, et al. Optimal vitamin D status: a critical analysis on the basis of evidence-based medicine. J Clin Endocrinol Metab 2013; 98(8): E1283–E1304.

43. Lappe JM, Binkley N. Vitamin D and Sarcopenia/Falls. J Clin Densitom 2015; 18(4): 478–482.

44. American Geriatrics Society Workgroup on Vitamin D Supplementation for Older Adults. Recommendations abstracted from the American Geriatrics Society Consensus Statement on vitamin D for prevention of falls and their consequences. J Am Geriatr Soc 2014; 62(1): 147–152.

45. Bischoff-Ferrari HA, Dawson- -Hughes B, Platz A, et al. Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. Arch Intern Med 2010; 170(9): 813–820.

46. Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, et al. Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med 2016; 176(2): 175–183.

47. Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol 2014; 2(4): 307–320.

48. Rizzoli R, Boonen S, Brandi ML, et al. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). CurrMed Res Opin 2013; 29: 305– 313.

49. Verbrugge F, Gielen E, Milisen K, Boonen S. Who should receive calcium and vitamin D supplementation? Age Ageing 2012; 41(5): 576–580.

50. Tom SE, Adachi JD, Anderson FA Jr, et al. Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc 2013; 61: 327–334.

51. Body JJ, Bergmann P, Boonen S, et al. Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int 2011; 22: 2769–2788.

52. Gerdhem P, Ringsberg KA, Akesson K. The relation between previous fractures and physical performance in elderly women. Arch Phys Med Rehabil 2006; 87: 914–917.

53. AGS/BGS/AAOS Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc 2001; 49: 664–672.

54. Robertson MC, Campbell AJ, Gardner MM, et al. Preventing injuries in older people by preventing falls: a metaanalysis of individual- level data. J Am Geriatr Soc 2002; 50: 905–911.

55. Howe TE, Rochester L, Neil F, et al. Exercise for improving balance in older people. Cochrane Database Syst Rev 2011.

56. Sherrington C, Henschke N Why does exercise reduce falls in older people? Unrecognised contributions to motor control and cognition? Br J Sports Med 2013; 47: 730–731.

57. Kanemaru A, Arahata K, Ohta T, et al. The efficacy of home-based muscle training for the elderly osteoporotic women: the effects of daily muscle training on quality of life (QoL). Arch Gerontol Geriatr 2010; 51: 169–172.

58. Batsis JA, Villareal DT. Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies. Nat Rev Endocrinol 2018; 14(9): 513–537.

59. American Geriatrics Society 2012 Beers Criteria Update Expert Panel American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60: 616–631.

60. Rizzoli R, Branco J, Brandi M-L, et al. Management of osteoporosis of the oldest old. Osteoporos Int 2014; 25: 2507–2529.

61. Ensrud KE, Black DM, Palermo L, et al. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial. Arch Intern Med 1997; 157(22): 2617– 2624.

62. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348(9041): 1535–1541.

63. Axelsson KF, Wallander M, Johansson H, et al. Hip fracture risk and safety with alendronate treatment in the oldest old. J Intern Med 2017; 282(6): 546–559.

64. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344(5): 333–340.

65. Masud T, McClung M, Geusens P. Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. Clin Interv Aging 2009; 4: 445–449.

66. Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52(11): 1832–1839.

67. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809–1822.

68. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357(18): 1799– 1809.

69. Boonen S, Black DM, Colon Emeric CS, et al. Efficacy and safety of a once yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 2010; 58(2): 292–299.

70. Black DM, Delmas PD, Eastell R, et al. Once yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809–1822.

71. Reid IR, Horne AM, Mihov B, et al. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women. J Bone Miner Res 2020; 35(1): 20–27.

72. Reid IR, Horne AM, Mihov B, et al. Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 2018; 379(25): 2407–2416.

73. Lee SH, Rigas N, Martin CE, et al. Zoledronic acid impairs oral cancer stem cells by reducing CCL3. Oncol Rep 2021; 45(1): 291–298.

74. McClung MR, Boonen S, Torring O, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res 2012; 27(1): 211–218.

75. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361(8): 756–765.

76. Boonen S, Adachi JD, Man Z, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2011; 96(6): 1727–1736.

77. Bonnet N, Bourgoin L, Biver E, et al. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest 2019; 129(8): 3214– 3223.

78. Phu S, Bani Hassan E, Vogrin S, et al. Effect of denosumab on falls, muscle strength, and function in community dwelling older adults. J Am Geriatr Soc 2019; 67(12): 2660–2661.

79. Chotiyarnwong P, McCloskey E, Eastell R, et al. A pooled analysis of fall incidence from placebo controlled trials of denosumab. J Bone Miner Res 2020; 35(6): 1014–1021.

80. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hor¬mone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344(19): 1434–1441.

81. Boonen S, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54(5): 782–789.

82. Boonen S, Marin F, Mellstrom D, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc 2006; 54(5): 782–789.

83. Walsh JB, Lems WF, Karras D, et al. Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 2012; 90(5): 373– 383.

84. Niimi R, Kono T, Nishihara A, et al. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age. Osteoporos Int 2016; 27(5): 1869–1874.

85. Tsourdi E, Langdahl B, Cohen-Solal M, et al. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 2017; 105: 11–17.

86. Sempos CT, Binkley N. 25-hydroxyvitamin D assay standardisation and vitamin D guidelines paralysis. Public Health Nutr 2020; 23(7): 1153–64.